Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06VWL
|
|||
| Former ID |
DNC009631
|
|||
| Drug Name |
VA-106483
|
|||
| Synonyms |
Fedovapagon; UNII-VX2GBO4I0V; 347887-36-9; VX2GBO4I0V; VA-106483; CHEMBL518043; Fedovapagon [INN]; SCHEMBL2547119; DTXSID40188331; MolPort-042-665-819; BDBM50246575; ZINC38471398; DB11734; NCGC00386702-01; 1,2-Pyrrolidinedicarboxamide, N2,N2-dimethyl-N1-((2-methyl-4-((2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)methyl)-, (2S)-; (2S)-N2,N2-dimethyl-N1-((2-Methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Nocturia [ICD-11: MF55; ICD-10: R35] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H34N4O3
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)C(=O)N2CCCCC3=CC=CC=C32)CNC(=O)N4CCCC4C(=O)N(C)C
|
|||
| InChI |
1S/C27H34N4O3/c1-19-17-21(25(32)30-15-7-6-10-20-9-4-5-11-23(20)30)13-14-22(19)18-28-27(34)31-16-8-12-24(31)26(33)29(2)3/h4-5,9,11,13-14,17,24H,6-8,10,12,15-16,18H2,1-3H3,(H,28,34)/t24-/m0/s1
|
|||
| InChIKey |
RUOLFWZIFNQQGH-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 347887-36-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V2 receptor (V2R) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Vasopressin-regulated water reabsorption | ||||
| Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (s) signalling events | ||||
| Vasopressin regulates renal water homeostasis via Aquaporins | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Regulation of Water Balance by Renal Aquaporins | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01038843) Efficacy Study of VA106483 in Males With Nocturia.. U.S. National Institutes of Health. | |||
| REF 2 | New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.